HemoShear Cancer Drug Discovery Platform Milestone
Wednesday, October 15, 2014
HemoShear has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations. Funded by a contract with the NCI, HemoShear is developing a series of tumor models that recreate a wide variety of cancers for discovery of new drugs.
Using their new platform, HemoShear was able to successfully replicate human therapeutic response to Cisplatin, a drug approved to treat non-small cell lung carcinomoa (NSCLC), at a therapeutically-relevant concentration. Similarly, HemoShear evaluated two other drugs currently in clinical studies and confirmed a therapeutic response.
When evaluated in traditional cell culture systems and mouse studies, the same exposure to Cisplatin does not show a response, demonstrating the potential advantage that HemoShear's tumor platform may have in predicting safety and efficacy of new cancer therapies.
"Nearly 95% of all cancer drugs entering clinical trials fail because of toxicity or lack of efficacy. A major contributor to this dismal failure rate can be attributed to the inability of traditional models to uncover the underlying disease biology and predict efficacy and safety of cancer drug candidates," said Brian Wamhoff, Ph.D., vice president of R&D and co-founder of HemoShear. "With our novel approach to recreating the tumor microenvironment, we have taken a major step toward understanding human response to cancer drug treatments."
"HemoShear's goal is to enter drug discovery collaborations with select pharmaceutical and biotechnology companies to identify novel therapeutic approaches. We believe that our best-in-class tumor systems will fundamentally improve success of these drug candidates when they enter the clinic and accelerate the time it takes to get to patients," said Vincent Aurentz, HemoShear's Chief Business Officer. "The results from this phase are very encouraging and allow us to engage potential partners in further development of the tumor microenvironment for specific programs where HemoShear can bring real value."